Ampyra, referred to as fampridine in some countries outside the US, is indicated for the treatment to improve walking in patients with multiple sclerosis (MS) in the US.
The patent covers methods of improving lower extremity function and walking and increasing walking speed in MS patients by administering less than 15mg of sustained release 4-aminopyridine (dalfampridine) twice a day.
The patent eligible for listing in the FDA Orange Book is set to expire in 2025.